Asia’s pan-regional buyout players are raising ever larger funds and pursuing ever larger deals. Is there now more capital in this segment of the market than places to – sensibly – put it?
At first glance, PAG Asia Capital’s acquisition of Yingde Gases appears to be a sign of the times. It is one of eight take-privates among 27 PE transactions of $1 billion or more announced – not all...
Even if pan-Asian buyout firms aren't actively pursuing investments in internet-related businesses, they cannot ignore the potential disruptive impact of these technologies on other portfolio companies
Mekong Capital's 6.3x return on its investment in Vietnam-based pharmaceuticals player Traphaco involved turning the company's distribution model on its head, as well as supporting expansion and improving governance
China Renaissance has added dedicated healthcare and mezzanine debt strategies to its existing growth-stage private equity offering as part of efforts to more than treble its assets under management (AUM) over the next three years.
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.